Machina Capital S.A.S. Raises Stake in Solventum Co. (NYSE:SOLV)

Machina Capital S.A.S. raised its stake in Solventum Co. (NYSE:SOLV) by 21.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,905 shares of the company’s stock after buying an additional 700 shares during the quarter. Machina Capital S.A.S.’s holdings in Solventum were worth $258,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Modus Advisors LLC purchased a new stake in Solventum in the 4th quarter valued at $25,000. Stonebridge Financial Group LLC purchased a new stake in Solventum in the 4th quarter valued at $26,000. Crews Bank & Trust purchased a new position in shares of Solventum during the 4th quarter worth $32,000. True Wealth Design LLC grew its holdings in shares of Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the period. Finally, Prospera Private Wealth LLC purchased a new position in shares of Solventum during the 3rd quarter worth $35,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on SOLV shares. The Goldman Sachs Group increased their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Morgan Stanley increased their price target on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Finally, Piper Sandler increased their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $79.86.

Solventum Price Performance

SOLV stock opened at $77.96 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market capitalization of $13.49 billion and a P/E ratio of 28.35. The business’s 50-day moving average is $73.65 and its two-hundred day moving average is $70.71. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.